Day: March 28, 2023

To NASDAQ Copenhagen A/S   Executive Board Lersø Parkalle 100 DK-2100 København Ø www.rd.dk Telephone +45 7012 5300 28 March 2023Company announcement number 24/2023 Fixing of coupon rate effective from 1 April 2023With effect from 1 April 2023, the coupon rate of the following bonds financing RD Euribor3®, RD Stibor3®, RD Stibor3® Green, RD Nibor3®, RD Cibor6® (RO), FlexGaranti® and RenteDyk® will be adjusted. Please find the data in the attached file.   The Executive Board Any additional questions should be addressed to Chief Analyst Hella Gebhardt Rønnebæk, Phone +45 45 13 20 68.AttachmentsNr. 24_Fastsaettelse af kuponrente pr. 01.04.2023_ukBilag til selskabsmeddelelse nr. 24-2023_uk

A/S Storebælt Annual Financial Report 2022AttachmentÅR_SBF_Årsrapport_2022_UK

CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) — Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the European Medicines Agency (EMA) issued a positive opinion on the Company’s application for orphan designation for SYNB1934 for the treatment of phenylketonuria (PKU). “We are pleased that the EMA has issued a positive opinion for orphan designation for SYNB1934, in recognition of the urgent need for new treatment options for people living with this devastating disease,” said Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Executive Officer. “This designation also comes at a pivotal time as we prepare to begin our Phase 3 trial for PKU in the first half of this year.” SYNB1934 has also been granted Rare Pediatric Disease Designation by the U.S....

A/S Øresund Annual Financial Report 2022AttachmentÅR_OSF_Årsrapport_2022_UK

MAINZ, Germany, March 28, 2023 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) today announced that it has entered into a new share repurchase program (the “Program”), pursuant to which the Company may purchase American Depositary Shares, each representing one ordinary share (“ADS”), of the Company in the amount of up to $0.5 billion during the remainder of 2023. BioNTech expects to use all or a portion of the repurchased ADSs and the ADSs held in treasury to satisfy upcoming settlement obligations under the Company’s share-based payment arrangements.  The timing and total amount of ADS repurchases will depend upon market conditions and may be made in open market purchases from time to time. The share repurchase program announced on March 31, 2022 of up to $1.5bn concluded on March 17, 2023 with a total...

EB Control vetted and approved by CIS’s rigorous evaluation process Jacksonville, Florida, March 28, 2023 (GLOBE NEWSWIRE) — Everything Blockchain Inc., (OTCMKTS: EBZT), a technology company that is blending blockchain, DBMS and Zero Trust to deliver disruptive new ways to store, manage and protect data, today announced a partnership with the Center for Internet Security, Inc. (CIS®) in the CIS CyberMarket®. CIS is a non-profit cybersecurity organization committed to keeping the connected world a safer place. Everything Blockchain, Inc. delivers novel solutions to the market that protect and securely store intellectual property. The company’s EB Control application safeguards data on the owner’s local device by creating a secure vault which can be stored, transported or shared; allowing the owner to maintain complete control...

To Nasdaq OMX Copenhagen A/S Public announcement no. 538March 28th, 2023 ANNUAL REPORT FOR GLUNZ & JENSEN HOLDING A/S FOR THE FISCAL YEAR 2022 AND EXPECTATIONS FOR THE FISCAL YEAR 2023 The annual report for the fiscal year 2022 was reviewed and approved at the Board of Directors meeting today. The Board of Directors are satisfied with the achievements and the financial results for 2022 – and announces the following consolidated financial statements for 2022 set for approval at the Annual General Meeting on April 19th, 2023. Please observe that the 2022 figures cover a 9-month period, whereas the 2021/22 figures cover a 12-month period. The annual report 2022 has the following key figures: The Group realized a revenue of DKK 103,4 million (2021/22: DKK 147,0 million). Gross profit totaled DKK 27,5 million (2021/22: DKK 39,1...

CHICAGO, IL, March 28, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Epazz Inc. (OTC: EPAZ), a mission-critical provider of drone technology, blockchain mobile apps and cloud-based business software solutions, announced today that ZenaDrone, Inc. received a letter of support from U.S. Air Force to use ZenaDrone 1000 for drone cargo delivery, which includes blood transport. ZenaDrone is invited to work with the U.S. Air Force at an overseas base to test the ZenaDrone 1000 platform under battlefield conditions. ZenaDrone will be assigned a team from the base to conduct the test. Over the past couple of months, ZenaDrone 1000 has been presented and showcased in front of the U.S. military. The company has been getting traction from the U.S. Air Force and U.S. Army. This test will be the first time ZenaDrone will be actively used in a...

Company announcement – No. 7 / 2023 Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396Dose-dependent body weight reductions of up to a mean of 4.2% from baseline (4.8% placebo corrected) following a single dose of ZP8396 In development as a non-incretin peptide therapy for the potential management of overweight and obesityCopenhagen, Denmark, March 28, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced Phase 1a results for ZP8396, the company’s amylin analogue. The first-in-human study was designed to assess safety, pharmacokinetic (PK) and pharmacodynamic effects of ZP8396 in healthy lean and overweight people. “We are excited by the potential of amylin as...